Latest News
and Innovations

Feb 7, 2025

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Jan 29, 2025

NewAmsterdam Pharma to Present at Guggenheim’s SMID Cap Biotech Conference

Jan 10, 2025

NewAmsterdam Pharma Highlights 2024 Achievements and Outlines 2025 Strategic Priorities

Jan 9, 2025

NewAmsterdam Pharma Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Dec 13, 2024

NewAmsterdam Pharma Announces Closing of Upsized $479.0 Million Public Offering of Ordinary Shares and Pre-Funded Warrants, Including Full Exercise of the Underwriters’ Option to Purchase Additional Shares

VIEW ALL NEWS
An anatomical heartAn anatomical heart

Driven by Patient Need,
Guided by Expertise

At NewAmsterdam Pharma, we are advancing a
new era of treatments for cardiovascular disease
(CVD) and other lipid-related conditions. By
prioritizing patients with unmet needs despite
currently available therapies, we are working
toward a reality where cardiovascular disease is no
longer the #1 killer of people worldwide.

LEARN MORE ABOUT US
A couple embracingA couple embracing

Developing a
Transformational Program

Guided by the latest clinical science and genetic research on CETP inhibition, our investigational asset, obicetrapib, was selected based on its potential ability to lower LDL-C and reduce cardiovascular risk.

DISCOVER OBICETRAPIB
Someone using a pipette to drop something in a petri dish